Trelstar

Not for use in women. Must administer under physician supervision. Discontinue if hypersensitivity occurs. Initial transient increase in serum testosterone may result in worsening of signs/symptoms including bone pain, neuropathy, hematuria, or urethral/bladder obstruction. Metastatic vertebral lesions and/or with urinary tract obstruction; monitor closely during the first few weeks of therapy. Spinal cord compression. Renal or hepatic impairment. May prolong QT/QTc interval in patients with congenital long QT syndrome, CHF, frequent electrolyte abnormalities. Correct any electrolyte abnormalities; monitor ECGs and electrolytes periodically. Metabolic changes (eg, hyperglycemia, diabetes, hyperlipidemia). Cardiovascular disease (eg, MI, sudden cardiac death, stroke). Monitor serum lipids, blood glucose and/or HbA1c periodically, and for signs/symptoms of cardiovascular disease. History of epilepsy. Intracranial tumors. Measure serum testosterone periodically. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.